Psilocybin
- Generic Name
- Psilocybin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H17N2O4P
- CAS Number
- 520-52-5
- Unique Ingredient Identifier
- 2RV7212BP0
- Background
Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.
- Associated Conditions
- -
- Associated Therapies
- -
Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients
- Conditions
- Interventions
- First Posted Date
- 2019-10-28
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 37
- Registration Number
- NCT04141501
- Locations
- 🇨🇭
Psychiatrische Universitätsklinik Zürich, Zürich, Switzerland
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 20
- Registration Number
- NCT04123314
- Locations
- 🇺🇸
Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States
Effects of Psilocybin in Anorexia Nervosa
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 22
- Registration Number
- NCT04052568
- Locations
- 🇺🇸
Behavioral Pharmacology Research Unit, Baltimore, Maryland, United States
A Study of Psilocybin for Major Depressive Disorder (MDD)
- Conditions
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Usona Institute
- Target Recruit Count
- 104
- Registration Number
- NCT03866174
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Cedar Clinical Research, Draper, Utah, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 233
- Registration Number
- NCT03775200
- Locations
- 🇺🇸
Kadima Neuropsychiatry Institute, La Jolla, California, United States
🇺🇸Altman Clinical and Translational Research Institute, University of California, San Diego, California, United States
🇺🇸Stanford Department of Psychiatry, Stanford, California, United States
Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 140
- Registration Number
- NCT03736980
Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 28
- Registration Number
- NCT03604744
- Locations
- 🇨🇭
Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland
Psilocybin and Depression
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2017-12-21
- Lead Sponsor
- University of Helsinki
- Target Recruit Count
- 60
- Registration Number
- NCT03380442
The Neurobiological Effect of 5-HT2AR Modulation
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Gitte Moos Knudsen
- Target Recruit Count
- 200
- Registration Number
- NCT03289949
- Locations
- 🇩🇰
Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark
Effects of Psilocybin in Major Depressive Disorder
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 27
- Registration Number
- NCT03181529
- Locations
- 🇺🇸
Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.